Phenyl Acetamides

1 . A compound of the formula

in which

A is a 4- to 7-membered nitrogen-containing saturated heterocycle which is bonded via the nitrogen atom to the keto group,

or

is a radical

in which

E is (C 4 -C 7 )-cycloalkanediyl or (C 1 -C 6 )-alkanediyl,

R 3 is hydrogen or methyl and

* is the point of linkage to the keto group,

n is 0, 1 or 2,

R 1 is hydrogen or (C 1 -C 6 )-alkyl,

R 2 is hydrogen or (C 1 -C 6 )-alkyl,

and

Z is located in the meta or para position and

is a radical *-G-L-M-R 4

in which

G is O,

L is (C 1 -C 6 )-alkanediyl,

M is a bond or O,

R 4 is (C 6 -C 10 )-aryl, biphenyl, phenoxyphenyl, benzyloxyphenyl, (E)-phenylvinylphenyl, 2-phenylethylphenyl, tetrahydronaphthyl, benzyl, heteroaryl, 5- to 10-membered heterocyclyl, (C 3 -C 7 )-cycloalkyl or (C 3 -C 7 )-cycloalkylmethyl, where aryl, biphenyl, phenoxyphenyl, benzyloxyphenyl, (E)-phenylvinylphenyl, 2-phenylethylphenyl, tetrahydronaphthyl, benzyl, heteroaryl, heterocyclyl, cycloalkyl and cycloalkylmethyl in turn may be substituted up to three times independently of one another by halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, (C 2 -C 6 )-alkenyl, (C 3 -C 7 )-cycloalkyl, (C 3 -C 7 )-cycloalkylmethoxy, (C 5 -C 7 )-cycloalkenyl, (C 3 -C 7 )-cycloalkoxy or (C 5 -C 7 )-cycloalkenyloxy, and

* is the point of linkage to the phenyl ring,

or a salt, solvate, or solvate of a salt thereof.

2 . The compound as claimed in claim 1 , characterized in that

A is a 4- to 6-membered nitrogen-containing saturated heterocycle which is bonded via the nitrogen atom to the keto group,

or

is a radical

in which

E is cyclopentanediyl, cyclohexanediyl, methylene, ethane-1,2-diyl or propane-1,3-diyl,

R 3 is hydrogen, and

* is the point of linkage to the keto group,

n is 0 or 1,

R 1 is hydrogen,

R 2 is hydrogen,

and

Z is located in the meta or para position and

is a radical *-G-L-M-R 4

in which

G is O,

L is (C 1 -C 4 )-alkanediyl,

M is a bond or O,

R 4 is phenyl, naphthyl, biphenyl, phenoxyphenyl, benzyloxyphenyl, (E)-phenylvinylphenyl, 2-phenylethylphenyl, tetrahydronaphthyl, benzyl, 1,3-dioxanyl, 1,4-dioxanyl, dimethyl-1,3-dioxanyl, tetrahydro-2H-pyranyl, (C 3 -C 7 )-cycloalkyl or (C 3 -C 7 )-cycloalkylmethyl, where phenyl, naphthyl, biphenyl, phenoxyphenyl, benzyloxyphenyl, (E)-phenylvinylphenyl, 2-phenylethylphenyl, tetrahydronaphthyl, benzyl, cycloalkyl and cycloalkylmethyl in turn may be substituted up to three times independently of one another by halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, (C 3 -C 7 )-cycloalkyl, (C 3 -C 7 )-cycloalkylmethoxy or (C 3 -C 7 )-cycloalkoxy, and

* is the point of linkage to the phenyl ring,

or a salt, solvate, or solvate of a salt thereof.

3 . The compound as claimed in claim 1 , characterized in that

A is acetidine, pyrrolidine or piperidine which is bonded via the nitrogen atom to the keto group,

or

is a radical

in which

E is cyclopentanediyl, cyclohexanediyl, methylene, ethane-1,2-diyl or propane-1,3-diyl,

R 3 is hydrogen, and

* is the point of linkage to the keto group,

n is 0 or 1,

R 1 is hydrogen,

R 2 is hydrogen,

and

Z is located in the para position and

is a radical *-G-L-M-R 4

in which

G is O,

L is methylene, propane-1,3-diyl or butane-1,4-diyl,

M is a bond or O,

R 4 is phenyl, 4-biphenyl, 4-phenoxyphenyl, 4-benzyloxyphenyl, 1,2,3,4-tetrahydronaphth-6-yl, 5,5-dimethyl-1,3-dioxan-2-yl or cyclohexyl, where phenyl in turn may be substituted by halogen, trifluoromethoxy, (C 3 -C 4 )-alkyl, (C 3 -C 4 )-alkoxy, cyclopentyl, cyclohexyl or (C 3 -C 6 )-cycloalkyl-methoxy, and

* is the point of linkage to the phenyl ring,

or a salt, solvate, or solvate of a salt thereof.

4 . The compound as claimed in claim 1 , characterized in that

A-[CH 2 ] n —CO 2 R 1 is a radical

in which

* is the point of linkage to the keto group,

R 2 is hydrogen,

and

Z is located in the para position and is

a radical *—O—CH 2 —R 4 ,

in which

R 4 is phenyl, 4-biphenyl, 4-phenoxyphenyl, 4-benzyloxyphenyl or 1,2,3,4-tetrahydronaphth-6-yl, where phenyl in turn may be substituted by trifluoromethoxy, n-propyl, n-butyl, tert-butyl, n-propyloxy, isopropyloxy, isobutyloxy, cyclohexyl or cyclopropylmethoxy, and

* is the point of linkage to the phenyl ring,

or

is a radical *—O—CH 2 —CH 2 —CH 2 —R 4

in which

R 4 is 4-chlorophenyl, 5,5-dimethyl-1,3-dioxan-2-yl or cyclohexyl, and

* is the point of linkage to the phenyl ring,

or

is a radical *—O—CH 2 —CH 2 —CH 2 —CH 2 —O—R 4

in which

R 4 is phenyl or cyclohexyl, and

* is the point of linkage to the phenyl ring,

or a salt, solvate, or solvate of a salt thereof.

5 . The compound as claimed in claim 1 , characterized in that

A is acetidine, pyrrolidine or piperidine which is bonded via the nitrogen atom to the keto group,

or

is a radical

in which

E is cyclopentanediyl, cyclohexanediyl, methylene, ethane-1,2-diyl or propane-1,3-diyl,

R 3 is hydrogen, and

* is the point of linkage to the keto group,

n is 0 or 1,

R 1 is hydrogen,

R 2 is hydrogen,

and

Z is located in the para position and is a radical

in which

* is the point of linkage to the phenyl ring,

or a salt, solvate, or solvate of a salt thereof.

6 . The compound as claimed in claim 1 , characterized in that

A-[CH 2 ] n —CO 2 R 1 is a radical

in which

* is the point of linkage to the keto group,

R 2 is hydrogen,

and

Z is located in the para position and is a radical

in which

* is the point of linkage to the phenyl ring,

or a salt, solvate, or solvate of a salt thereof.

7 . A process for preparing a compound of the formula (I) as defined in claim 1 or one of its salts, solvates or solvates of its salts, characterized in that

either

(A) a compound of the formula (II)

in which

R 2 is (C 1 -C 6 )-alkyl,

Q 1 is hydroxy or chlorine, and

Z has the meaning indicated in claim 1 ,

is reacted with a compound of the formula (III)

in which

R 1 is (C 1 -C 6 )-alkyl, and

n and A have the meaning indicated in claim 1 ,

or

(B) the two ester groups —C(O)OR 1 and —C(O)OR 2 in a compound prepared by process step (A) are hydrolyzed.

8 . (canceled)

9 . A pharmaceutical composition comprising a compound as defined claim 1 in combination with an inert, non-toxic, pharmaceutically suitable excipient.

10 . A pharmaceutical composition comprising a compound as defined in claim 1 in combination with a further active ingredient.

11 . A method for the treatment and/or prophylaxis of cardiovascular disorders comprising administering an effective amount of a compound as defined in claim 1 .

12 . (canceled)

13 . (canceled)

14 . The use method as claimed in claim 11 wherein the cardiovascular disorder is unstable angina pectoris or myocardial infarction.